Company Dossier · Health Care
Amgen
- S&P 500
- S&P 100
- Nasdaq-100
- Dow 30
- Russell 1000
What Amgen is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $38.1 billion, up 9.1% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $10.2 billion, down 4.1% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $2.30 billion, up 63% from a year earlier.SEC EDGAR filings (XBRL)
- Latest earnings call or results release (August 4, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 3 outlook figures raised, 0 lowered, 4 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 13, 2026): 11 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $4.1 million on the open market.SEC Form 4
- 3,169 institutional managers reported a position at June 30, 2026 (+16 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 185 (222 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Amgen is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Expanding · Confident
Expanding ↔ Retrenching
Expanding
- Capital spending88th pct
- Debt raised—
- Buybacks vs capex—
- Hiring filings88th pct
- Deals and private raises40th pct
- Patent publications22nd pct
Confident ↔ Hedging
Confident
- Call sentiment93rd pct
- Call confidence90th pct
- Guidance changes66th pct
- Risk factors added7th pct
- Insider open-market trades44th pct
- + Call sentiment
- + Call confidence
- − Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver88th pct
- Stress filings95th pct
Credit
How these are built →Amgen's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$57.3B
- Due within a year $5.4B
- Longer term $51.9B
- Default point $31.4B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
$4.0B
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Feb 17, 2026 | $1B | 4.200% | 2031 (5y) | +60bp | 4.223% |
| Feb 17, 2026 | $1.75B | 4.850% | 2036 (10y) | +82bp | 4.872% |
| Feb 17, 2026 | $500M | 5.500% | 2046 (20y) | +90bp | 5.532% |
| Feb 17, 2026 | $750M | 5.650% | 2056 (30y) | +97bp | 5.655% |
From the pricing term sheets Amgen filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Amgen: guidance raised minus lowered
Guidance Ledger statements by quarter
Amgen: earnings call sentiment
Palanor Discourse score per call, −1 to +1
Hiring and ownership
In the news
Headlines that name Amgen, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralAmgen Inc (AMGN) Shares Fall 3.4% -- GF Value Says Still Overvalued
gurufocus.com · via Marketaux · Oct 1, 2026
- NeutralAmgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors
gurufocus.com · via Marketaux · Sep 30, 2026
- NeutralAmgen reports a Phase 3 win with Sjögren’s drug candidate
BioPharma Dive · Sep 22, 2026
- NeutralKaryopharm pushes off debt payment; Amgen eyes broader Imdelltra use
BioPharma Dive · Sep 11, 2026
- NeutralNew data could widen use of AstraZeneca, Amgen immune disease drug
BioPharma Dive · Aug 27, 2026
- Neutral
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (THE NICKLES GROUP, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (MARSHALL & POPP, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (AMGEN, INC.)third_quarter 2026 · $3.1 million
- Oct 20, 2026LobbyingLobbying report (ACG ADVOCACY)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (AVENUE SOLUTIONS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (WILLIAMS AND JENSEN, PLLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Jul 31, 20268-KCybersecurity incidentItem 1.05
- May 20, 20268-KShareholder vote resultsItem 5.07
- May 19, 20268-KDirector or officer changeItem 5.02
- Apr 22, 20268-KDirector or officer changeItem 5.02
- Feb 19, 20268-KMaterial agreement signedItem 1.01
- Feb 13, 202610-KAnnual report (10-K)11 risk factors added, 0 removed
- Jan 30, 20268-KMaterial agreement terminatedItem 1.02
- May 27, 20258-KShareholder vote resultsItem 5.07
- Feb 14, 202510-KAnnual report (10-K)0 risk factors added, 2 removed
- Feb 14, 202410-KAnnual report (10-K)2 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Gilead Sciences GILD | $30.5B | $12.9B | Jun 30, 2026 |
| Regeneron Pharmaceuticals REGN | $15.5B | $3.8B | Jun 30, 2026 |
| Vertex Pharmaceuticals VRTX | $12.6B | $3.8B | Jun 30, 2026 |
| Biogen BIIB | $9.9B | $2.4B | Mar 31, 2026 |
| Incyte INCY | $5.4B | — | Mar 31, 2026 |
| Neurocrine Biosciences NBIX | $3.4B | $0.6B | Jun 30, 2026 |
| United Therapeutics UTHR | $3.1B | $1.1B | Jun 30, 2026 |
| Exelixis EXEL | $2.4B | $1.2B | Jul 3, 2026 |